Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Open-Label, Single Arm Study to Assess the Safety of AQUAVAN® (Fospropofol Disodium) Injection for Minimal-to-Moderate Sedation in Patients Undergoing Minor Surgical Procedures

NCT00327392 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT00327392
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00327392 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Open-Label, Single Arm Study to Assess the Safety of AQUAVAN® (Fospropofol Disodium) Injection for Minimal-to-Moderate Sedation in Patients Undergoing Minor Surgical Procedures
Lead sponsor
Eisai Inc.
Phase
Phase 2/3
Overall status
Completed
Start date
May 31, 2006
Completion date
December 31, 2007
Enrollment
123 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

procedural sedation